"Pharmaceutical Headline Jun" Central Commission for Discipline Inspection issued a serious crackdown on medical corruption

(2020/09/04) Treatment of Type 2 Diabetes Lilly Trulicity adds two new high-dose labels; 100 billion market cap drug companies rise Fosun 35 innovative drugs exposed 17 new Class 1 drugs bright eyes; drugstore remote review of the accident ... (Click on the title to get the original article) "Pharmaceutical 1st Time" treatment type 2 diabetes Lilly Trulicity added two new high-dose labels on September 3rd, and the FDA approved two additional doses of Lilly Trulicity (dulaglutide, dolate peptide).
this approval expanded trulicity's weekly allergy label by 3.0 mg and 4.5 mg doses, mainly based on positive results from the AWARD-11 study.
the three-phase trial showed that two additional doses could further improve glycoglobin (HbA1c) and lose weight in people with type 2 diabetes compared to 1.5 mg Trulicity.
: Extra doses of Trulicity will be available in U.S. pharmacies in late September.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
so far Fosun Pharma has 22 varieties over-evaluated (13 for the first), 11 varieties of winning national collection.
Innovation research and development into the harvest period, Hanlikang monthly revenue exceeded 100 million yuan, the first introduction of small-molecule innovative drug Avaquopa, the second bio-similar drug querceta single anti-approved market;
: Half-year net profit exceeded $1.7 billion.
Recently, the public interest litigation department of the Honggang District People's Procuratorate of Daqing City, Heilongjiang Province, received the above-mentioned reply when it supervised and inspected the practice of pharmacy pharmacists in the district.
investigation, prosecutors in Daqing City, Honggang District, the relevant drugstore distribution sales records compared with attendance records, found that several pharmacies have a practicing pharmacist off-duty sales of prescription drugs violations.
: The drugstores involved did not meet the requirements of the remote reviewer.
, the Central Commission for Discipline Inspection issued a serious crackdown on medical corruption On September 2, the official website of the Central Commission for Discipline Inspection of the Communist Party of China (CPC) published a special article, "Taking the case as a mirror" chengdu to seriously rectify corruption in the medical field.
The article exposed a hospital original equipment supply section of a violation of the central eight provisions of the spirit and integrity discipline, accept management object red envelope gifts, take official opportunities to change travel;
headlines: All pharmaceutical companies and representatives should be vigilant.
the first half of the domestic PD-1 sales of nearly 4 billion yuan, the domestic market local / foreign investment ranking flip? With Hengrui Pharmaceuticals, Xinda Biologicals, Baiji Shenzhou and Junshi Bio-Report, the four major domestic PD-1 sales performance in the first half of this year is also basically clear.
addition to "as always" do not disclose PD-1 sales of Hengrui Pharmaceuticals, the other three have disclosed the specific sales of their own PD-1.
headlines: There's going to be a battle for health care.